Picoplatin Overcomes Resistance to Cell Toxicity in Small-cell Lung Cancer Cells Previously Treated with Cisplatin and Carboplatin

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2010 Sep 3

PMID 20809122

Citations 13

Authors

Chi-Hui Tang

Christi Parham

Ellyn Shocron

Gerald McMahon

Neela Patel

Affiliations

Soon will be listed here.

Abstract

Purpose: Picoplatin is a new generation platinum designed to overcome platinum resistance. The goal of this study was to assess picoplatin anti-tumor activity and measure various cellular parameters in small-cell lung cancer (SCLC) cells resistant to cell killing by cisplatin and carboplatin.

Methods: We developed several platinum-resistant SCLC cell lines to evaluate picoplatin activity and drug resistance mechanisms in vitro. Drug cytotoxicity was measured by MTS assay. Total cellular platinum accumulation was measured by inductively coupled plasma mass spectrometry (ICP-MS). Whole genome gene expression profiling was carried out by microarray analysis.

Results: Picoplatin retained significant cytotoxic activity in platinum-resistant SCLC lines compared to cisplatin and carboplatin. Cellular picoplatin accumulation in platinum-resistant and parental cells was high relative to levels of cellular platinum found in the same cell lines after cisplatin or carboplatin treatment. Gene expression analyses revealed substantial differences in gene expression and highlighted specific annotation clusters in carboplatin-resistant cells. In addition, a similar gene expression pattern was observed in picoplatin-treated carboplatin-resistant and parental cells.

Conclusions: Our study demonstrates that picoplatin can overcome carboplatin and cisplatin resistance. The results suggest decreased platinum accumulation as a potential mechanism of platinum resistance in SCLC cells, provide candidate markers (e.g. several genes in the Hox, glutathione biosynthetic process, and MAGE families) that may serve as signatures for platinum resistance, support distinct effects of picoplatin on SCLC cells compared to other platinums, and provide a rationale to develop picoplatin for the treatment of recurrent SCLC following initial therapy with cisplatin or carboplatin.

Citing Articles

ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.

Wiedemeyer W, Gavrilyuk J, Schammel A, Zhao X, Sarvaiya H, Pysz M Mol Cancer Ther. 2022; 21(6):986-998.

PMID: 35642431 PMC: 9381089. DOI: 10.1158/1535-7163.MCT-21-0851.

Platinum Complexes in Colorectal Cancer and Other Solid Tumors.

Koberle B, Schoch S Cancers (Basel). 2021; 13(9).

PMID: 33922989 PMC: 8123298. DOI: 10.3390/cancers13092073.

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages.

Janke F, Bozorgmehr F, Wrenger S, Dietz S, Heussel C, Heussel G Cancers (Basel). 2020; 12(4).

PMID: 32290637 PMC: 7226444. DOI: 10.3390/cancers12040954.

Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy.

Shi Q, Shen L, Dong B, Fu H, Kang X, Dai L Thorac Cancer. 2018; 9(7):836-846.

PMID: 29757528 PMC: 6026615. DOI: 10.1111/1759-7714.12758.

Increased HOXC6 expression predicts chemotherapy sensitivity in patients with esophageal squamous cell carcinoma.

Shen L, Fan M, Dong B, Yan W, Chen K Oncol Lett. 2017; 14(4):4835-4840.

PMID: 29085488 PMC: 5649700. DOI: 10.3892/ol.2017.6772.

References

Bracht K, Boubakari , Grunert R, Bednarski P . Correlations between the activities of 19 anti-tumor agents and the intracellular glutathione concentrations in a panel of 14 human cancer cell lines: comparisons with the National Cancer Institute data. Anticancer Drugs. 2005; 17(1):41-51. DOI: 10.1097/01.cad.0000190280.60005.05. View

Goddard P, Valenti M, Kelland L . The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts. Anticancer Res. 1994; 14(3A):1065-70. View

Stordal B, Davey M, Davey R . Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Cancer Chemother Pharmacol. 2005; 58(2):256-65. DOI: 10.1007/s00280-005-0148-7. View

Rubin E, Wu X, Zhu T, Cheung J, Chen H, Lorincz A . A role for the HOXB7 homeodomain protein in DNA repair. Cancer Res. 2007; 67(4):1527-35. DOI: 10.1158/0008-5472.CAN-06-4283. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Shears L, Plowright L, Harrington K, Pandha H, Morgan R . Disrupting the interaction between HOX and PBX causes necrotic and apoptotic cell death in the renal cancer lines CaKi-2 and 769-P. J Urol. 2008; 180(5):2196-201. DOI: 10.1016/j.juro.2008.07.018. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Raynaud F, Boxall F, Goddard P, Valenti M, Jones M, Murrer B . cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res. 1998; 3(11):2063-74. View

Sugita M, Geraci M, Gao B, Powell R, Hirsch F, Johnson G . Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res. 2002; 62(14):3971-9. View

10.

Konstantinopoulos P, Fountzilas E, Pillay K, Zerbini L, Libermann T, Cannistra S . Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics. 2008; 1:59. PMC: 2613398. DOI: 10.1186/1755-8794-1-59. View

11.

Boubakari , Bracht K, Neumann C, Grunert R, Bednarski P . No correlation between GSH levels in human cancer cell lines and the cell growth inhibitory activities of platinum diamine complexes. Arch Pharm (Weinheim). 2004; 337(12):668-71. DOI: 10.1002/ardp.200400620. View

12.

Eckardt J, Bentsion D, Lipatov O, Polyakov I, Mackintosh F, Karlin D . Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009; 27(12):2046-51. DOI: 10.1200/JCO.2008.19.3235. View

13.

Yuan Y, Wang F, Liu X, Gong D, Cheng H, Huang S . Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer. 2009; 66(1):28-36. DOI: 10.1016/j.lungcan.2008.12.027. View

14.

Lee H, Lee D, Park M, Yang S, Lee J, Kim D . STMN2 is a novel target of beta-catenin/TCF-mediated transcription in human hepatoma cells. Biochem Biophys Res Commun. 2006; 345(3):1059-67. DOI: 10.1016/j.bbrc.2006.05.017. View

15.

Yamashita T, Tazawa S, Yawei Z, Katayama H, Kato Y, Nishiwaki K . Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int J Oncol. 2006; 28(4):931-8. View

16.

Helleman J, Jansen M, Span P, van Staveren I, Massuger L, Meijer-Van Gelder M . Molecular profiling of platinum resistant ovarian cancer. Int J Cancer. 2005; 118(8):1963-71. DOI: 10.1002/ijc.21599. View

17.

Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E . Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A. 2000; 97(23):12776-81. PMC: 18840. DOI: 10.1073/pnas.97.23.12776. View

18.

Huang D, Sherman B, Lempicki R . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4(1):44-57. DOI: 10.1038/nprot.2008.211. View

19.

Scielzo C, Ghia P, Conti A, Bachi A, Guida G, Geuna M . HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest. 2005; 115(6):1644-50. PMC: 1136999. DOI: 10.1172/JCI24276. View

20.

Mellish K, Kelland L, HARRAP K . In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer. 1993; 68(2):240-50. PMC: 1968570. DOI: 10.1038/bjc.1993.322. View